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ABSTRACT
Gastric cancers are a significant cause of morbidity worldwide.
Epidemiological studies and animal models show that males have
higher incidences of gastric cancers compared with females, suggest-
ing that sex hormones may modulate gastric cancer risk. An animal
model of the initiation phase of gastric cancer was used to determine
the effects of systemic estrogen administration on morphological pro-
gression of preneoplastic lesions and to define cell populations at
which estrogens may act. Preneoplastic progression in antral and
duodenal mucosa was examined in male rats that received the chem-
ical carcinogen, N-methyl-N9-nitro-nitrosoguanidine (MNNG), dur-
ing treatment with implants containing 17b-estradiol or oil vehicle.
Histopathological changes in antral and duodenal gland morphology,
numbers of proliferating cells and apoptotic bodies, and antral gastrin
cell numbers and protein storage levels were determined 4 weeks
later. With MNNG treatment, duodenal villous heights were signif-
icantly decreased, and epithelial cells displayed histological features
of hyperplasia and dysplasia. Antral glands showed epithelial hyper-
plasia and dysplasia, increased mucosal height, and decreased mucin
levels. Antral gastrin storage protein levels were decreased by
MNNG. Systemic treatment with 17b-estradiol significantly reversed
MNNG-induced alterations in duodenal gland heights while increas-
ing mucin and gastrin levels in antral glands. Cell proliferation and
apoptosis rates were not significantly different between groups. The
present results indicate that systemic 17b-estradiol treatment influ-
ences antral and duodenal gland differentiation during the initiation
phase of chemical gastroduodenal carcinogenesis in male rats. These
results explain, in part, a potential pathway through which protective
effects of estrogens on chemical carcinogenesis are mediated in the
upper gastrointestinal tract. (Endocrinology 140: 4886–4894, 1999)
GASTRIC CANCER is one of the most common neo-plasms worldwide, and numerous clinical and ex-
perimental studies suggest that sex hormones alter gastric
cancer risk (1–3). Gastric cancer incidence rates are approx-
imately 2-fold higher in males than in females in nearly every
country studied. Differences in sex ratios also depend on
gastric site as ratios for proximal cancers are approximately
7-fold higher in males than females (4). Estrogen replacement
therapy (ERT) in postmenopausal women significantly re-
duces the incidence of colorectal adenocarcinomas (reviewed
in Ref. 5). Epidemiological studies for effects of ERT on
gastric cancer risk have not been performed in the United
States, though a trend for risk reduction was found in Italian
women (6). Women with late onset of menopause also have
a reduced risk of gastric cancer (7). Several groups have
clearly shown a higher incidence for experimental gastric
tumors in male animals compared with females (rats, mice,
hamsters) (8–11).
Environmental factors are important etiological factors in
human gastric carcinogenesis with N-nitrosamino com-
pounds the most commonly investigated agents. These com-
pounds are found in cured meats, some drinking water, and
certain vegetables. They can be converted by certain bacteria
such as Helicobacter pylori into nitrosamines that have been
found to cause gastric cancer in animals. Chronic adminis-
tration of N-methyl-N9-nitro-N-nitrosoguanidine (MNNG)
in drinking water to rats produces adenocarcinomas in the
distal glandular stomach (antrum) and upper small intes-
tines (duodenum) (11–15). The MNNG model has been used
extensively to study mechanisms of human chemical gastric
carcinogenesis because the antral adenocarcinomas share
gender-related incidences, histological features, and distri-
bution patterns with human upper gastrointestinal (GI) ad-
enocarcinomas (11, 16). MNNG acts directly on upper GI
epithelial cells, causing methylation of DNA and proteins. It
is rapidly converted to N-methyl-N9-nitroguanidine that is
not carcinogenic. Adenocarcinomas develop at the gastric
lesser curvature wherein higher cell proliferative rates and
thiol concentrations may increase local susceptibility (17, 18).
Large differences have been observed in the sensitivity of
different rat strains to MNNG-induced tumors (reviewed in
Ref. 19). These differences were observed following identical
treatment with MNNG in the drinking water. Male Wistar
and ACI rats were very sensitive to MNNG, whereas male
Sprague Dawley rats had intermediate sensitivity and Buf-
falo rats were resistant. Several parameters have been stud-
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ied to account for genetic differences in sensitivity to MNNG
that include MNNG metabolism by N-denitrosation, tissue
glutathione levels, O-methylguanine demethylation (DNA
repair), and cell proliferation rates (19, 20). Of all these fac-
tors, cell proliferation rate (number and range of distribu-
tion) was the only factor that predicted strain sensitivity (20).
Thus, the proliferative response of the gastric mucosa was
proposed to be a key factor in the difference of susceptibility
to gastric carcinogens between male rats of various strains.
Within these strains, gender differences in tumor inci-
dence have also been determined (21). Rats were adminis-
tered MNNG (83 mg/ml) in their drinking water for 8 months
and were killed at 18 months. The incidence of gastric ade-
nocarcinoma in ACI rats was 80% in males and 47% in fe-
males. In contrast, the incidence was 18% in males and 0%
in females in Buffalo rats. The F1 progeny of sensitive (ACI)
and resistant (Buffalo) stains had a dominant resistant phe-
notype in males and sensitive phenotype in females (17%
male vs. 8% female). These incidences indicate complex in-
teractions between MNNG susceptibility and gender.
Sprague Dawley rats are reported to have intermediate sen-
sitivity (19, 22), but gender incidences have been not re-
ported. In another study, administration of MNNG for 4
months with tumor incidences determined at 12 months
resulted in gastric carcinomas in 80% of Wistar male rats
compared with an incidence of , 6% of ovariectomized and
intact female rats (8). Castration decreased the incidence to
30%. Another report from the same laboratory showed a
slight reduction in tumor incidences in male rats receiving
estradiol treatment (88% vs. 68% (23). Estradiol was admin-
istered as twice weekly injections (400 mg/kg) for 4 months
starting 2 months after beginning MNNG treatment. This
evidence suggests that female hormones suppress, and male
hormones promote, gastric cancer risk. Although male rats
are known to be more susceptible than females to MNNG-
induced gastric tumors, the gender-specific mechanism has
not been investigated.
Estrogens regulate cell growth and differentiation in nu-
merous tissues in both females and males and have critical
roles in breast and uterine carcinogenesis (24). Estrogens act
on cells through intracellular estrogen receptors (ER) that
regulate target gene expression although nongenomic effects
have also been reported (25). Recently, two ER subtypes, ERa
and ERb, have been characterized with differences in tissue
distribution, ligand binding, transcriptional activity, and
dimerization specificity (26–28). Expression of both ERa and
ERb have been reported in epithelial cells of the upper GI
tract with a predominance of ERb over ERa expression (29–
31). Additional complexity would be expected in those cell
types that express both receptors as ER homodimer (ERa/
ERa; ERb/ERb) or heterodimer (ERa/ERb) formation can
occur (32).
Mechanisms for protective effects of estrogens in gastric
carcinogenesis are not known and could involve direct ef-
fects on mucosal cells, indirect effects mediated through
other agents, or both. As a first step in identifying the roles
of estrogens in GI carcinogenesis, a rat model for human
gastric cancer was used to examine the influence of systemic
estrogen exposure on morphological progression of preneo-
plastic lesions and to define the cell populations at which
estrogens may act. Systemic and local effects of 17b-estradiol
administration were examined in male rats that received sc
implants of 17b-estradiol (E2) or oil vehicle before and dur-
ing the initiation phase of gastroduodenal carcinogenesis
induced by MNNG.
Materials and Methods
Reagents
Serum testosterone and estradiol levels were determined by RIA at
Equitech Labs (Alachua, FL). MNNG was purchased from Aldrich,
Milwaukee, WI). All other reagents were obtained from Sigma (St. Louis,
MO) or Fisher Scientific (Norcross, GA).
Animals and experimental protocol
Young adult male Sprague Dawley rats (6 weeks old, weight ;150 g,
n 5 48; Harlan Sprague Dawley, Inc., Indianapolis, IN) were used. All
experiments were approved by the Institutional Animal Care and Use
Committee using protocols according to the NIH Guide for the Care and
Use of Laboratory Animals and by the Environmental Health and Safety
office at the University of Florida. Rats were randomly assigned in
groups of 2–3/cage and housed on wood chips (14-h light, 10-h dark
cycle). Rats were acclimated to a powdered diet (AIN 76A, Tekland,
Madison, WI) containing casein protein rather than soy protein, a major
source of genistein and other phytochemicals with potential estrogenic
activity (33). Following 1 week on the AIN diet, rats were anesthetized
and SILASTIC brand silicon tubing (Dow Corning, Midland, MI) con-
taining either 17b-estradiol (E2; 300 mg/ml in sesame oil; Sigma) or oil
vehicle were placed sc as previously described (29). All implants were
replaced after 2.5 weeks.
One week following the first implant placement, rats were given
MNNG (CAS: 70–25-7)(100 mg/ml, (12)) or plain tap water. Stock so-
lutions of MNNG (1 mg/ml in tap water) were prepared fresh weekly
and stored at 4 C. The stock solution was diluted with tap water just
before use and placed in a tin-foil covered bottle to prevent photolysis
of MNNG. Food and water intakes were recorded and drinking solu-
tions replenished three times a week. Weekly body weights were
determined.
After 4 weeks of MNNG treatment and 2 h before they were killed,
rats received an injection of the thymidine analog bromo-deoxyuridine
(BrdU; 50 mg/kg ip) to label cells in the S phase of the cell cycle. Two
hours later, rats were anesthetized with sodium pentobarbital (60 mg/
kg) and the abdominal aorta was cannulated for serum collection and
in vivo perfusion with 100 ml phosphate buffer (PBS, 10 mm KPO4, 150
mm NaCl, pH 7.4) followed by 200 ml 2% paraformaldehyde-lysine-
periodate (PLP) (34). During perfusion, the stomach was distended with
2 ml PLP. The stomach and duodenum (proximal 5 cm) were removed
and opened and ingesta rinsed off with PBS. Tissues were postfixed
overnight in PLP at 4 C. Sections of fundus, antrum (midline on lesser
curvature) and duodenum were embedded in paraffin for light micros-
copy. Sections from antrum were embedded in Lowicryl resin for im-
munogold labeling as previously described (35) or in plastic resin (TAAB
812, Merivac, Halifax, Nova Scotia). Blood samples were collected before
perfusion, stored on ice for 30 min, and spun at 3000 3 g for 20 min.
Serum was collected and stored at 275 C.
Histopathology
Alterations in mucosal morphology were determined on sections
immersion-fixed in 10% formalin and stained with hematoxylin-eosin
for nuclear detail and periodic acid-Schiff (PAS) histochemistry for mu-
cin staining. Histological classification of lesions was made using es-
tablished criteria from human pathology for grade of dysplasia (0–3
scale, none to severe) (36). Sections were coded so that the observer
(GYL) was unaware of the treatment group.
Image analysis
Antral gland heights and duodenal villus height and crypt depth
were measured in regions in which full-length glands were oriented
perpendicular to the submucosa. Height of antral and duodenal glands
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was measured using a Carl Zeiss Axiophot microscope fitted with a 103
objective and 1.25 optivar setting. Images were captured with a video
camera (Hamamatsu C2400, Hamamatsu City, Japan) linked to a per-
sonal computer with frame grabber and image analysis software (Vidas
2.1, Carl Zeiss, Thornwood, NY). The image analysis system was cali-
brated for each objective and optivar combination by tracing a reference
distance on a stage micrometer. For each rat, 5–8 antral glands were
measured in proximal, middle and distal regions. Duodenal villous and
crypt heights were measured in four to eight glands from proximal and
distal regions in each rat. Total duodenal gland height was calculated as
the sum of villous and crypt height for each gland.
Gastrin immunogold analysis
Gastrin protein levels within storage granules were quantified by
immunogold analysis. Ultrathin sections were placed on formvar-coated
nickel grids and incubated with 0.1 m NH4Cl for 1 h. Grids were washed
in Tris buffer (TBS; 10 mm Tris HCl, pH 7.5, 150 mm NaCl) followed by
blocking buffer (10 mm Tris HCl, pH 7.5, 500 mm NaCl, 1% BSA). Grids
were incubated with rabbit polyclonal antibodies to gastrin (1:500) in
blocking buffer overnight at 4 C followed by washing in TBS. Grids were
incubated with goat antirabbit antiserum conjugated with 15 nm gold
particles (1:200, Amersham Pharmacia Biotech) followed by washing
with TBS. Sections were counterstained with uranyl acetate and lead
citrate before examination using a Carl Zeiss transmission electron mi-
croscope. Gastrin cells were randomly selected and cells containing a
nucleus were photographed. Storage granules were selected from pho-
tographs (;16,000 final magnification) and defined as symmetrical gray
densities 0.3–0.7 mm in diameter. Gold particles within four to eight
storage granules were counted and data expressed as average number
per storage granule/cell. This average was then used to calculate a mean
value for each rat (4–7 gastrin cells/rat). Controls for immunogold
staining included replacement of the primary antisera with normal
rabbit serum or PBS.
Immunohistochemistry for BrdU incorporation and gastrin
cell numbers
Cells in the S phase of the cell cycle and gastrin-producing neuroen-
docrine cells were counted following immunohistochemistry. Following
rehydration to PBS, tissue sections were placed in citrate buffer (10 mm,
pH 6.0) and heated in a microwave at full power (750 W) for 10 min with
buffer replenishment every 2.5 min. Sections were cooled for 20 min at
room temperature and washed in PBS for 5 min. Sections were incubated
in 10% normal goat serum for 10 min following by the primary antibody
overnight at 4 C (mouse monoclonal anti-BrdU peroxidase conjugate,
Roche Molecular Biochemicals; rabbit polyclonal anti-gastrin). Sections
were washed in PBS and incubated in 3% H2O2/PBS for 10 min to
inactivate endogenous peroxidase. Sections were incubated for 10 min
with peroxidase conjugated antirabbit antibodies for gastrin cell detec-
tion. Immunoreactivity was localized by incubation with diaminoben-
zidine tetrahydrochloride substrate. Cell counting was performed in
regions with glands oriented perpendicular to the submucosa. Numbers
of positive BrdU nuclei and gastrin cells in the antral glands were
counted in five to eight rectangular reference frames with the 403
objective and 1.6 optivar setting. Number of positive BrdU nuclei in
duodenal crypts were counted as above using the 203 objective and 2.0
optivar setting. The reference frame from the imaging system was over-
laid on the section with the shortest side aligned at the muscularis
mucosa to encompass four to five glands. The viewer was unaware of
treatment conditions.
Apoptosis rates in antral glands
Several methods are available for determining rates of apoptosis
including morphological assessment on stained sections and in situ DNA
end labeling methods (37, 38). Cell necrosis following inadequate fix-
ation has been reported to effect apoptosis rates determined by the end
labeling method in the rat intestinal tract (38). The accuracy of apoptosis
detection was enhanced by using semithin plastic resin sections with
toluidine blue staining rather than using H&E sections (39). Cells un-
dergoing apoptosis were estimated by counting numbers of apoptotic
cell bodies/500 cells. Apoptotic bodies were identified as small, round
cells with dense nuclear staining surrounded by a distinct clear cyto-
plasm. Cells in the entire antral gland unit were counted from superficial
epithelium to the base of glands in regions where glands were oriented
perpendicular to the submucosa.
Data analysis
Three independent experimental trials were performed with 2–6
rats/treatment group in each trial. Data are presented as mean 6 sem
(N 5 number of rats/treatment group) and were analyzed by one-way
ANOVA with posthoc t-tests for significant differences (P , 0.05).
Results
Morphological alterations in antrum and duodenum
induced by MNNG
Data in Fig. 1 show that MNNG induced striking alter-
ations in antral and duodenal gland morphology. In the
antrum, MNNG induced mucosal hyperplasia and surface
epithelial dysplasia (Fig. 1B). Nuclear alterations were ob-
served in surface cells following MNNG. Surface epithelial
cells in the proximal glandular region (gastric fundus) did
not show hyperplasia or dysplasia (not shown). Staining for
mucin, determined by PAS histochemistry, was reduced
throughout the antral glands particularly in superficial and
neck mucous cells. Grade of antral dysplasia was signifi-
cantly increased compared with control (Table 1) and dys-
plastic foci or adenocarcinoma were detected in two animals.
In contrast, MNNG induced duodenal villus shortening and
widening and mucosal hyperplasia and epithelial dysplasia
(Fig. 1, D–F). Systemic 17b-estradiol treatment modulated
glandular alterations induced by MNNG in both antrum and
duodenum. Mucin staining was increased to control levels
throughout the antral glands following 17b-estradiol treat-
ment (Fig. 1C). As well, antral dysplastic foci or adenocar-
cinomas were not observed and grade of dysplasia was im-
proved by 17b-estradiol treatment (Table 1). Duodenal gland
heights were increased in 17b-estradiol treated rats (Fig. 1F).
These data show that MNNG induced differential patterns of
changes in antral and duodenal glands and that these alter-
ations could be modulated by 17b-estradiol administration.
Antral and duodenal gland heights were quantified using
a calibrated image analysis system. MNNG treatment re-
sulted in significantly increased antral mucosal gland
heights, whereas duodenal gland heights were decreased
(Fig. 2). These effects represented an increase of 164% in
antral gland height and a decrease of 47% in duodenal villous
height compared with control rats. Duodenal crypt height
was not changed by MNNG treatment (Fig. 2). 17b-Estradiol
administration significantly reversed MNNG-induced alter-
ations in duodenal total gland and villous heights. Increases
in antral gland heights induced by MNNG were slightly
decreased by 17b-estradiol cotreatment (P 5 0.068) (Fig. 2).
Thus, 17b-estradiol treatment primarily had a protective ef-
fect on duodenal gland height in this model.
Antral gastrin protein levels
Neuroendocrine gastrin cells were studied to further an-
alyze effects of MNNG on cell differentiation in the antral
mucosa. Similar numbers of gastrin cells were found in all
groups (Fig. 3). The effect of MNNG on intracellular gastrin
protein levels was quantified using immunogold analysis.
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Immunoreactivity for gastrin was found in the small, elec-
tron dense storage granules, over intracellular membranes
and occasionally within the nucleus (Fig. 4). 17b-estradiol
treatment significantly increased gastrin levels in storage
granules compared with MNNG treatment alone (Fig. 4).
Control conditions for the immunogold analysis using
replacement of the primary antibody with normal rabbit
serum or PBS showed occasional nuclear labeling in various
cell types (not shown). Gastrin antisera was specific for gas-
trin producing cells as other cell types including neuroen-
docrine somatostatin and serotonin cells and their respective
storage granules were not immunoreactive (not shown).
Cell proliferation and apoptosis rates
We next used BrdU immunohistochemistry to evaluate the
effects of MNNG on antral and duodenal crypt cells under-
going DNA synthesis in the S phase of the cell cycle. In antral
FIG. 1. Alterations in antral (A–C) and duodenal (D–F) gland morphology induced by MNNG. Tissue sections were stained with hematoxylin
and periodic acid-Schiff (PAS). Rats were untreated (A, D), MNNG (B, E) or MNNG and 17b-estradiol implants (C, F) as described in Materials
and Methods. For antral sections, sections are aligned at the muscularis mucosa (MM) as shown in a control panel (A). Antral mucosa in
MNNG-treated rats (B) is thicker with hyperplasia and dysplasia of the superficial epithelium (SE). MNNG treatment resulted in reduced mucin
staining (pink) throughout the glands. MNNG and 17b-estradiol treatment (C) reduced superficial dysplasia and increased mucin staining
throughout the antral glands. In panels D–F, duodenal glands consist of upper villous (V) and lower crypt (C) regions as shown on the left of
a control panel (D). Sections are aligned across villous crypt junctions of representative sections. Villi in the MNNG group (E) are blunted and widened.
MNNG and 17b-estradiol-treated rats (F) had increased villous heights. Original magnifications: antrum, 803; duodenum, 62.53.
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glands following MNNG administration, the number of pro-
liferating cells was increased approximately 2.5-fold and
their position within the gland shifted from the base upward
toward the superficial epithelium (Fig. 5). Proliferating cells
were detected in the superficial epithelium of an antral ad-
enocarcinoma that developed in an MNNG-treated rat (Fig.
5). Quantitation of the antral labeling index showed that
pretreatment with 17b-estradiol did not decrease antral cell
proliferation induced by MNNG (Fig. 5). Similarly in the
duodenum, MNNG-induced increases in the labeling index
(1.6-fold) were not significantly altered by 17b-estradiol co-
treatment (Fig. 5).
Rates of apoptosis were estimated using morphological
criteria for apoptotic bodies on plastic sections by light mi-
croscopy. Numbers of apoptotic bodies were significantly
increased following MNNG treatment (Fig. 6). 17b-estradiol
cotreatment did not alter this endpoint.
General animal health in the MNNG model
Rats given MNNG appeared to be in good health but had
decreased weight gain (Table 2). Food intake tended to be
lower in the MNNG-treated groups particularly in the rats
with 17b-estradiol implants (Table 2). Testicular weights,
when normalized to body weight, were not altered by 17b-
estradiol treatment and serum testosterone levels were not
significantly different between groups (Table 2). Serum es-
trogen levels measured 18 days following placement of 17b-
estradiol implants were similar to those in normal cycling
female Sprague Dawley rats from our lab (12.3 6 3 vs. 12.0 6
3 pg/ml, respectively, n 5 6/group). These serum levels are
similar to other published levels for physiological ranges of
estradiol fluctuations during normal estrus cycles (40). The
control and MNNG males had serum estrogen concentra-
tions of 7.7 6 2 and 6.2 6 1 pg/ml, respectively (n 5
5/group). These values are similar to previously reported
serum estrogen levels in male rats (41).
Discussion
The majority of experimental studies on the development
of human gastric adenocarcinoma have been performed in
the rat. Various therapeutic agents enhance or suppress the
carcinogenic activity of MNNG (42–46). The present study
examined whether systemic estrogens could modify preneo-
plastic alterations induced by MNNG. The MNNG model
was chosen because gender differences, histopathological
characteristics and distribution patterns mimic those ob-
served in human upper GI adenocarcinomas (11, 16). An
earlier report showed a slight decrease in tumor incidence in
Wistar male rats receiving 17b-estradiol injections when
started 2 months after MNNG treatment (23). In our study,
exposure to 17b-estradiol began 1 week before and continued
throughout MNNG exposure for 1 month.
The present study confirms earlier reports that preneo-
plastic proliferative lesions are observed as early as 4 weeks
following MNNG treatment and that these early changes
correlate with tumor development (14, 45). A greater sus-
ceptibility to the carcinogenic effects of MNNG has been
reported for the upper small intestine (duodenum) com-
pared with the glandular stomach in rats with preneoplastic
alterations consisting of villus blunting and crypt elongation
as shown in this study (15, 47). We present new data showing
TABLE 1. Morphological preneoplastic changes in antral glands
in control rats and rats receiving MNNG and oil vehicle (MNNG)
or 17b-estradiol implants (MNNG1E2)
Treatment N DysplasiaGrade
Dysplastic
foci (N)
Carcinoma
(N)
Control 9 0.2 6 0.2 0 0
MNNG 9 1.83 6 0.4a 1 1
MNNG1E2 8 1.25 6 0.3 0 0
Data are mean 6 SEM.
a P , 0.05 vs. Control.
FIG. 2. 17b-estradiol treatment modulates alterations in mucosal
gland heights induced by MNNG. Antral (A) gland and duodenal (B)
total gland, villous and crypt heights were measured on formalin
embedded sections using a calibrated image analysis system. 17b-
estradiol significantly increased duodenal total gland and villous
heights during MNNG administration (MNNG 1 E2), whereas antral
gland heights tended to decrease compared with MNNG. Duodenal
crypt heights were significantly increased following MNNG 1 E2
compared with controls. Mean 6 SEM, n 5 8–9, a, P , 0.05 from
control; b, P , 0.05 from MNNG (ANOVA).
FIG. 3. Gastrin cell numbers were not altered by MNNG treatment.
Gastrin cells were stained by immunohistochemistry and numbers of
positive cells per field of view were counted as described in Materials
and Methods. Mean 6 SEM, n 5 4–6.
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FIG. 4. 17b-estradiol treatment increased gastrin immunoreactivity during MNNG treatment. Gastrin protein levels in storage granules were
estimated by immunogold analysis as described in Materials and Methods. Representative photomicrographs of gastrin cells from MNNG (A,
B) and MNNG1E2 (C, D) treated rats (original magnification ;16,0003). Regions (stars) within each cell have been enlarged and prints
developed with less contrast to emphasize localization of gold particles (arrows) within storage granules (arrowheads). E, Numbers of gold
particles/storage granule were significantly increased by MNNG and 17b-estradiol treatment. Mean 6 SEM, a, P , 0.05 from MNNG, n 5 4–6.
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that the upper intestine is a particularly sensitive site for
estrogenic protection. These data are compelling in light of
the probable protective effect of estrogen replacement ther-
apy on reducing large intestinal, i.e. colon, cancer risk in
postmenopausal women (reviewed in Ref. 5). Altered mucus
secretion is also a premalignant alteration observed follow-
ing MNNG treatment (48, 49). This study shows that mucin
levels were similar to control conditions in rats receiving
MNNG and 17b-estradiol treatments.
MNNG treatment resulted in antral cell hyperplasia with
displacement of stem cells toward the superficial epithelium.
These changes are considered obligatory preneoplastic le-
sions that increase the potential for direct stem cell exposure
to MNNG (49). One potential mechanism of action of estro-
gens on mucosal cells could involve modulation of stem cells
leading to reductions in cell proliferation. The present study
shows a significant increase in number of cells undergoing
DNA synthesis in antral glands and duodenal crypts fol-
lowing MNNG treatment. These alterations in labeling in-
dices paralleled changes in antral gland and duodenal crypt
heights. 17b-estradiol administration did not alter prolifer-
ation rates under these conditions. A compensatory mech-
anism for excessive cell proliferation is an increased rate of
programmed cell death or apoptosis (50). Apoptosis rates
were increased following MNNG treatment but were not
altered by 17b-estradiol treatment. More sensitive detection
methods, such as ultrastructural analysis by electron micros-
copy, may be required to detect significant differences be-
tween treatment groups, if they exist, as basal rates of apo-
ptosis in the antrum are very low (37, 50). Apoptosis rates in
human gastric carcinomas are closely associated with cell
proliferation rates and apparently do not have biological
significance as a prognostic factor (51).
Gastrin is a well-characterized hormonal regulator of
proximal gastric and duodenal cell growth and mucosal bar-
rier production (52, 53). Gastrin is synthesized as a prohor-
mone, and following processing in the Golgi apparatus, is
concentrated in small electron dense storage granules that
contain several processing enzymes (54). This study reports
FIG. 5. Distribution and numbers of S phase cells in antral and du-
odenal glands following MNNG. Antral stem cells in S phase of the
cell cycle were detected by incorporation of bromodeoxyuridine fol-
lowed by immunohistochemistry. Sections are aligned at the muscu-
laris mucosa (MM). In control rats (A), few positive nuclei were de-
tected in the base of antral glands. MNNG treatment (B) increased
numbers of proliferating cells with an upward shift of the prolifer-
ating zone toward the superficial epithelium (SE). 17b-estradiol co-
treatment with MNNG (C) did not significantly alter position of pro-
liferating cells. D, Section of an antral adenocarcinoma from a male
rat treated with MNNG demonstrating neoplastic glands and exten-
sion of proliferating cells to the surface epithelium (arrow). Original
magnifications: A–C, 803; D, 403. E, BrdU-positive nuclei were
counted in antral glands and duodenal crypts as described in Mate-
rials and Methods. MNNG and MNNG 1 E2 treatments significantly
increased numbers of proliferating cells. Data are expressed as num-
ber/field of view (labeling index) (mean 6 SEM for n 5 4–6; a P , 0.05
from control).
FIG. 6. Numbers of apoptotic bodies in antral glands following
MNNG treatment. Apoptotic cell bodies were counted in antral glands
from resin embedded sections as described in Materials and Methods.
Rates of apoptosis were increased by MNNG and MNNG1E2 treat-
ments. Data are expressed as number/500 cells (mean 6 SEM, n 5 3–5,
a, P , 0.05 from control).
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for the first time that gastrin protein levels in storage gran-
ules are significantly increased following MNNG and 17b-
estradiol treatments. The differences in intragranular gastrin
protein levels are not expected to yield significant alterations
in serum gastrin levels as gastrin cell numbers and messen-
ger RNA steady-state levels (data not shown) are not dif-
ferent between groups. The effects of sex steroid hormones
on serum gastrin levels have been studied. In Sprague Daw-
ley rats and guinea pigs, males have higher levels of serum
gastrin levels than females and serum levels correlate with
antral gastrin concentrations or gastrin cell numbers (55–57).
However, 17b-estradiol treatment in either castrated or
ovariectomized rats does not significantly lower serum gas-
trin levels implying that estrogens alone may not have a role
in gender differences (55, 56). In contrast, 17b-estradiol ad-
ministration in ovariectomized mice results in significant
increases in serum gastrin levels (58).
The effects of systemic estrogens on differentiation of mu-
cous and gastrin cells could result from improved mucosal
barrier function as both cell types have apical membranes
raising the potential for direct exposure to luminal MNNG.
This proposal is supported by studies showing protective
roles of estrogens in acute rat gastric injury models (59).
Interestingly, estrogens were prescribed at one time for du-
odenal ulcers in humans (60). Mechanisms for improved
mucosal barrier function could result from alterations in
MNNG metabolism or luminal pH. Gender differences in
glutathione levels and antioxidant enzymes are known for
different regions of the rat GI tract (61). Glutathione levels are
significantly higher in gastric and duodenal mucosa of fe-
male Sprague Dawley rats compared with males (61). How-
ever, higher glutathione levels would probably increase
MNNG susceptibility (18, 19, 62). Glutathione peroxidase
activity is also significantly higher in gastric mucosa of fe-
males compared with males (61). 17b-estradiol treatment
decreases gastric acid secretion in ovariectomized rats how-
ever MNNG is more efficiently absorbed at higher pH levels
(63, 64). Taken together, these data suggest a mechanism
distinct from known effects of estrogens in the upper GI
tract for mediating protective effects during MNNG
carcinogenesis.
Our data confirm decreased body weight gain following
MNNG treatment (14) and further show that decreased body
weight gain was associated with small reductions in food
intake. Reduction of appetite by estrogens has been previ-
ously reported (65). As expected, rats treated with both 17b-
estradiol and MNNG had decreased weight gain and food
intake, with testicular weights reduced in parallel with body
weights. These changes occurred with serum testosterone
levels remaining similar between treatment groups.
Despite the severity of lesions induced by MNNG, sys-
temic estrogen treatment in male rats resulted in significant
protective effects. Direct effects in mucosal cells, secondary
effects mediated by other agents, or both, could mediate
protective effects. The potential for a direct effect is suggested
by studies showing that ER, particularly the recently iden-
tified ERb subtype, are expressed in rat antral and duodenal
epithelium (29, 66). In another study using male rats, expression
of antral ERa, determined by RIA, remained constant while
androgen and epidermal growth factor receptors declined
throughout the course of MNNG treatment (67). ER expression
in GI epithelial cells suggests that direct hormonal manip-
ulation of cell function is possible. Further studies in con-
junction with in vitro cell culture models and ER gene knock-
out animal models (68), particularly those with deletions for
ERb, are needed to further test this proposal. Such studies
would have relevance for understanding potential mecha-
nisms by which female hormones reduce GI cancer risk.
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